Friday, December 6, 2024 12/6/2024

Using data science to measure the impact of opioid agonist therapy in patients admitted with Staphylococcus aureus bloodstream infections

Award Number: K08DA048163
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

Group Awards By:

View Award Abstract

PROJECT SUMMARY/ABSTRACT This career development award will provide early career support for investigation of the management of infec- tious diseases in the setting of addiction in hospitals. The award will provide support for the candidate to develop expertise in the following areas: 1) addiction science research; 2) natural language processing; 3) machine learn- ing; 4) professional development; and 5) responsible conduct of research. For this, Dr. Goodman-Meza will be mentored by a multidisciplinary, cross-institutional team with expertise in addiction, infectious diseases, and data science. His primary mentor, Dr. Steve Shoptaw, has an extensive track record in addiction-related research and training of future independent investigators. His co-mentors include Dr. Alex Bui and Dr. Matthew B. Goetz. Dr. Bui is an expert in biomedical data science and heads NIH training programs in this field. Dr. Goetz has broad experience of productive infectious diseases clinical research within the Veterans Health Administration (VHA). The current opioid epidemic in the United States has been associated with an increase in infections, in particular hepatitis C and bacterial infections. Bacterial infections are the leading infectious diagnosis leading to hospitali- zation in individuals with an opioid use disorder (OUD), and incur significant healthcare expenditures. Despite the availability of opioid agonist therapy (OAT) in the form of methadone or buprenorphine, less than 20% of people with OUD actually receive OAT. Hospitalization for a bacterial infection may be an ideal time to initiate OAT, but the benefits of this practice are unknown. In this proposal, the candidate will assess the impact of initiating OAT in people who inject opioids admitted to the VHA due to a Staphylococcus aureus blood stream infection (bacteremia) – the most common bacterial pathogen among people who inject opioids. Using data already collected for 36,868 cases of S. aureus bacteremia (SAB) from the VHA electronic data repository, the candidate will address three research questions: 1) is a natural language processing algorithm (NLP) more ac- curate than a standard International Classification of Diseases (ICD) code-based approach at screening records to correctly identify individuals who inject opioids in a cohort of patients admitted with SAB; 2) what are the temporal and geographic trends of SAB in people who inject opioids and those who receive OAT at the facility- level; and 3) using a machine learning framework, what are the estimated impacts of OAT on patient centered outcomes – death, readmissions, leaving against medical advice, and subsequent outpatient engagement in OAT. These formative data will help the candidate to establish a productive early career as a physician-scientist and advise development of an OAT-delivery strategy to mitigate infectious complications of injection opioid use. Through this award, Dr. Goodman-Meza will establish himself as an expert physician-scientist at the intersection of infectious disease and addiction, poised to make significant contributions to this important area of medicine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$28,692 )
2025	2023	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	5	10/10/2024	NON-COMPETING CONTINUATION	-$28,692
														Subtotal = -$28,692

Issue Date FY: 2023 ( Subtotal = $203,040 )
2023	2023	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	5	5/25/2023	NON-COMPETING CONTINUATION	$203,040
														Subtotal = $203,040

Issue Date FY: 2022 ( Subtotal = $203,040 )
2022	2022	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	4	5/5/2022	NON-COMPETING CONTINUATION	$203,040
														Subtotal = $203,040

Issue Date FY: 2021 ( Subtotal = $203,040 )
2021	2021	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90095	LOS ANGELES	USA	Drug Abuse and Addiction Research Programs	000	3	5/21/2021	NON-COMPETING CONTINUATION	$203,040
														Subtotal = $203,040

Issue Date FY: 2020 ( Subtotal = $203,040 )
2020	2020	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90095	LOS ANGELES	USA	Drug Abuse and Addiction Research Programs	000	2	5/14/2020	NON-COMPETING CONTINUATION	$203,040
														Subtotal = $203,040

Issue Date FY: 2019 ( Subtotal = $203,040 )
2019	2019	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90095	LOS ANGELES	USA	Drug Abuse and Addiction Research Programs	000	1	6/11/2019	NEW	$203,040
														Subtotal = $203,040

Grand Total All Awards = $986,508

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Using data science to measure the impact of opioid agonist therapy in patients admitted with Staphylococcus aureus bloodstream infections

Award Number: K08DA048163

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer